Published in Eur J Cancer on March 01, 2010
Use of the MLPA assay in the molecular diagnosis of gene copy number alterations in human genetic diseases. Int J Mol Sci (2012) 1.21
Role of DNA methylation in renal cell carcinoma. J Hematol Oncol (2015) 1.02
TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene (2014) 0.81
The epigenetic landscape of renal cancer. Nat Rev Nephrol (2016) 0.81
Tpl2 knockout keratinocytes have increased biomarkers for invasion and metastasis. Carcinogenesis (2013) 0.77
Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression. Int J Med Sci (2017) 0.75
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev (2004) 2.72
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci U S A (2007) 2.30
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol (2007) 1.96
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol (2007) 1.90
Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). Clin Chim Acta (2006) 1.89
Prognostic value of thrombocytosis in renal cell carcinoma. J Urol (2006) 1.87
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
Mapping and identification of essential gene functions on the X chromosome of Drosophila. EMBO Rep (2001) 1.83
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol (2009) 1.73
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol (2009) 1.61
Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem (2008) 1.60
Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol (2010) 1.60
Laparoscopic partial nephrectomy with clamping of the renal parenchyma: initial experience. Eur Urol (2007) 1.60
Nephron-sparing surgery is equally effective to radical nephrectomy for T1BN0M0 renal cell carcinoma: a population-based assessment. Urology (2009) 1.58
Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int (2012) 1.56
Cytoreductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. Urology (2008) 1.55
Thirty-day mortality after nephrectomy: clinical implications for informed consent. Eur Urol (2008) 1.53
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol (2007) 1.51
Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer (2009) 1.51
Raman spectroscopy: a novel experimental approach to evaluating renal tumours. Eur Urol (2010) 1.49
Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. BJU Int (2012) 1.48
Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol (2006) 1.48
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Optical spectroscopy techniques can accurately distinguish benign and malignant renal tumours. BJU Int (2012) 1.45
A contemporary population-based assessment of the rate of lymph node dissection for penile carcinoma. Ann Surg Oncol (2010) 1.43
[Kidney tumors]. Prog Urol (2007) 1.43
[Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer]. Prog Urol (2005) 1.43
C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer (2007) 1.43
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42
Detailed analysis of morbidity following nephrectomy for renal cell carcinoma in octogenarians. J Urol (2012) 1.42
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer. Arch Esp Urol (2010) 1.41
Overall mortality after radical nephrectomy in patients aged over 80 years with renal cancer: a retrospective study on preoperative prognostic factors. Int J Urol (2012) 1.41
The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality. J Urol (2009) 1.40
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes (2004) 1.39
Mucosal IL-10 and TGF-beta play crucial roles in preventing LPS-driven, IFN-gamma-mediated epithelial damage in human colon explants. J Clin Invest (2008) 1.38
Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood (2011) 1.37
Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27
Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology (2008) 1.26
Squamous cell carcinoma arising in a hepatic forgut cyst. Pathol Res Pract (2002) 1.23
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol (2012) 1.21
Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol (2009) 1.21
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol (2005) 1.20
A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int (2008) 1.20
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol (2013) 1.17
Genome-wide RNA interference analysis of renal carcinoma survival regulators identifies MCT4 as a Warburg effect metabolic target. J Pathol (2012) 1.14
Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol (2007) 1.13
Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer (2007) 1.11
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol (2003) 1.08
Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer (2010) 1.08
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol (2004) 1.06
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol (2007) 1.06
Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J (2008) 1.03
Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. Arch Esp Urol (2002) 1.03
[Management of acute prostatitis, based on a series of 100 cases]. Prog Urol (2005) 1.03
Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol (2009) 1.02
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ. Lab Invest (2002) 1.02
Transperitoneal laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. JSLS (2013) 1.01
Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol (2003) 1.00
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
The omega-6 fatty acid derivative 15-deoxy-Δ¹²,¹⁴-prostaglandin J2 is involved in neuroprotection by enteric glial cells against oxidative stress. J Physiol (2012) 1.00